Board of Directors

Steve Crane

BCom (University of Newcastle), FAICD, SF Fin
Independent Non-Executive Director

Industry Experience

Steve has more than 40 years’ of financial market experience, as well as a long and successful history of directorships of publicly-listed companies.

He began his career at AMP, working in funds management. When ABN AMRO acquired BZW Australia and New Zealand in 1998, Steve became Chief Executive and remained in this role until his retirement. Since then, he has been a member of boards in a variety of different sectors including banking, investment fund management, retail, property, resources and superannuation.

Steve has expertise in developing and leading international businesses, reviewing, scrutinising and implementing corporate strategy, people leadership and government interactions at senior levels.

Directorships of listed entities

Steve is a Non-Executive Director of APA, including APT Pipelines Limited and SCA Property Group.

Former directorships of listed entities in the past three years

None.

Other business and market experience

Steve has previously been a Non-Executive Director of Bank of Queensland, Transfield Services Limited, Investa Property Group (Chair), Foodland Associates, Adelaide Bank Limited, Adelaide Managed Funds, Investment Banking and Securities Association (Chair), APA Ethane Limited and a Trustee of ARIA (a Commonwealth employee superannuation fund).

Other commitments

Steve is Chair of Taronga Conservation Society Australia and Chair of Global Valve Technology Limited.

Interests in shares and performance rights

Indirect: 250,000 ordinary shares in nib holdings limited held by Depeto Pty Ltd.

Mark Fitzgibbon

MBA (University of Technology Sydney), MArts (Macquarie University), ALCA (Charles Sturt University), FAICD
Chief Executive Officer and Managing Director; Executive Director

Mark joined nib in October 2002 as Chief Executive Officer. In 2007 as Managing Director, he led nib through its demutualisation and listing on the Australian Securities Exchange (ASX) being admitted to the S&P/ASX 100 in 2019.

Mark is a Director of nib health funds limited, as well as many other nib holdings limited’s subsidiaries. He is also a member of nib holding’s Nomination Committee.

Industry experience

Mark has held executive positions at a number of large Australian organisations, including local government councils and peak bodies.

Leading nib for almost 20 years, Mark has transformed the business from a regionally based (Newcastle, NSW) private health insurer into one of Australia’s fastest growing and innovative health funds.

As Managing Director, Mark’s strategic focus has been to grow and diversify nib’s business and with that earnings by leveraging nib’s capability, systems and people. This has seen nib grow significantly in recent years organically and inorganically, both in existing and new markets.

Directorships of listed entities

None.

Former directorships of listed entities in the past three years

None.

Former directorships of listed entities in the last 3 years

None.

Other business and market experience

Mark has previously served as CEO of both the national and NSW peak industry bodies for licensed clubs, as well as holding several General Manager positions in local government.

Other commitments

Mark is currently a Director of Private Healthcare Australia.

Interests in shares and performance rights

Direct: 1,875,847 ordinary shares in nib holdings limited.

Indirect: 724,621 ordinary shares in nib holdings limited held by Fitzy (NSW) Pty Ltd.

225,978 performance rights under FY17-FY20 Long Term Incentive Plan which may vest from 1 September 201920.

222,298 performance rights under FY18-FY21 Long Term Incentive Plan which may vest from 1 September 2021.

215,962 performance rights under FY19-FY22 Long Term Incentive Plan which may vest from 1 September 2022.

200,362 performance rights under FY19-FY22 Long Term Incentive Plan which may vest from 1 September 2022.

Lee Ausburn

MPharm (University of Sydney), BPharm (University of Sydney), Dip Hosp Pharm (University of Sydney), FAICD 
Independent Non-Executive Director

Lee was appointed to the Board of nib holdings limited in November 2013. She is Chair of the People and Remuneration Committee and a member of the Risk and Reputation Committee and Nomination Committee.

She is also a Director of nib health funds limited.

Industry Experience

With more than 30 years’ experience in the pharmaceuticals industry, Lee has a wealth of knowledge in the global health industry.

Lee is a pharmacist with experience in retail and hospital pharmacy, as well as in academia. She had a long career in the pharmaceutical industry with Merck Sharp and Dohme (Australia) Pty Ltd and was previously Vice President – Asia for Merck and Co Inc with responsibility for the company’s operations across nine countries.

At Merck and Co Inc, Lee built high performing organisations with enhanced ethical and compliance frameworks, across the Asia Pacific region. She also has extensive marketing experience with customer centric approaches that had proven results with the region growing strongly under her leadership. Operating in a highly regulated industry, Lee also developed strong regulatory and government relations skills.

She also has experience operating joint ventures, including chairing the Far East Operating Board, overseeing the successful Merck-Schering Plough Asia Pacific Joint Venture from 2003 to 2007.

Directorships of listed entities

Lee is currently a Director of pharmaceutical wholesaling and pharmacy retail business, Australian Pharmaceutical Industries Ltd.

Former directorships of listed entities in the last 3 years

SomnoMed Ltd.

Other business and market experience

Lee was previously a member (2010-2015) and President (2015-2017) of the Pharmacy Foundation at the University of Sydney.

She’s also been an industry representative on the Australian Government’s Pharmaceutical Health and Rational Use of Medicines Committee (1993-1996) and the Drug Utilisation Subcommittee (1995-1997).

In NSW, she was a Board member of NSW Health’s Clinical Excellence Commission and the Agency for Clinical Innovation (2010-2014), established to enhance quality and safety in NSW hospitals.

Lee is currently a Mentor for Women on Boards.

Interests in shares and performance rights

Indirect: 20,000 ordinary shares in nib holdings limited held by Leedoc Pty Ltd and 30,885 ordinary shares in nib holdings limited held by MIML Pension Consolidator (Lee Ausburn).

Jacqueline Chow

BSc (Hons) (University of New South Wales), MBA (Northwestern University, Chicago), GAICD
Independent Non-Executive Director

Jacqueline was appointed to the Board of nib holdings limited in April 2018. She is Chair of the Risk and Reputation Committee and a member of the Nomination Committee, Audit Committee and People and Remuneration Committee.

he is also a Director of nib health funds limited.

Industry Experience

Jacqueline has more than 20 years’ experience working with global blue-chip consumer product multinationals in a range of executive and non-executive positions in general management, strategy, marketing as well as technology and innovation. Her early career concentrated on business analytics, brand equity and marketing.

With a reputation for driving growth and performance in global businesses, she is passionate about unlocking value through the entire value chain by growing consumer demand through disruptive technologies, innovation and digital platforms.

Directorships of listed entities

Jacqueline is currently a Non-Executive Director of Coles Group Limited.

Former directorships of listed entities in the last 3 years

None.

Other business and market experience

Jacqueline has significant global experience driving strategic growth and innovation across customer and consumer brands for the likes of Fonterra, Campbell Arnott’s and the Kellogg Company.

he was previously Deputy Chair of Global Dairy Platform and a Director of Fisher & Paykel Appliances in New Zealand, Dairy Partners Americas, the Riddet Institute (Massey University NZ) and The Arnott’s Foundation.

In her role with McKinsey & Company RTS, she advises clients across resources, retail, financial services, telecommunications and consumer sectors on organisational change and high performance culture.

Other commitments

acqueline is a Non-Executive Director of the Australia-Israel Chamber of Commerce and a senior advisor with McKinsey & Company RTS. She is also a member of Chief Executive Women.

Interests in shares and performance rights

Direct: 50,000 shares in nib holdings limited.

David Gordon

LLB (University of NSW), BCom (University of NSW)
Independent Non-Executive Director

David was appointed to the Board of nib holdings limited in May 2020. He is also a member of the Audit Committee, People and Remuneration Committee and Nomination Committee.

He is also a Director of nib health funds limited.

Industry Experience

David has over 20 years’ experience as a director of both public and private companies and has spent more than 30 years working in corporate advisory roles to Australian and international organisations. He brings extensive knowledge of mergers and acquisitions, as well as capital raisings, IPOs and joint ventures.

David also has a proven track record in guiding businesses to harness their digital asset capability to successfully explore and grow new markets.

Directorships of listed entities

David is currently Chair of Accent Group Limited.

Former directorships of listed entities in the past three years

Non-Executive Director and Chair of Ten Network Holdings Limited.

Other business and market experience

David has held a number of senior roles with Freehills (Partner) and boutique investment bank Wentworth Associates (acquired by Investec in 2001). In addition, he founded independent corporate advisory and investment firm, Lexicon Partners in 2001, where he still serves as Founding Principal.

Other commitments

avid is Chair of Ordermentum Pty Ltd and General Homecare Holdings Pty Ltd.
He is also a Non-Executive Director of Genesis Capital Investment Management Pty Ltd, General Medical Holdings Pty Ltd, Stilmark Holdings Pty Ltd and international not-for-profit organisation, High Resolves Pty Ltd.

Anne Loveridge

BA (Hons) (University of Reading), FCA, GAICD
Independent Non-Executive Director

Anne was appointed to the Board of nib holdings limited in February 2017. She is the Chair of the Audit Committee and a member of the Investment Committee, Risk and Reputation Committee and Nomination Committee.

She is also Chair of nib nz holdings limited’s Board, Audit, Risk and Compliance Committee.

In addition, Anne is a Director of nib health funds limited and nib nz holdings limited’s subsidiaries.

Industry Experience

Anne has over 35 years’ of experience in banking, wealth management, private equity and property.

She has extensive knowledge of financial and regulatory reporting, risk management controls and compliance frameworks. She also has experience as a Committee Chairperson and Non-Executive Director for three other ASX-listed organisations.

Formally trained as a Chartered Accountant, Anne has a breadth of experience in financial reporting, auditing, risk, ethics and regulatory affairs following her 31 years with PwC Australia, where she retired as Partner and Deputy Chair in 2015.

Through senior leadership roles in the firm, Anne also has experience and a focus on leadership, performance and culture. She was specifically involved in the creation of targets, mentoring and development programs for senior executives, as well as evaluating organisational training programs to identify areas of bias.

Anne Loveridge is entitled to receive a retirement benefit from PwC as part of her retirement plan. The amount of the payment was determined at the time of retirement, based on role and tenure with the firm. The benefit is not impacted by the revenue, profits or earnings of PwC. Anne has declared her previous relationship with PwC to the nib Board and the Board is satisfied that it does not affect her independence as Non-Executive Director and does not constitute a conflict of interest. The nib Board has in place mechanisms to manage conflicts of interest where they arise.

Directorships of listed entities

Anne is a Non-Executive Director of Platinum Asset Management (Chair of the Audit, Risk and Compliance Committee) and a Non-Executive Director of National Australia Bank Limited (Chair of the Remuneration Committee).

Former directorships of listed entities in the last 3 years

None.

Other commitments

Anne is Chair of Australian theatre company, Bell Shakespeare Limited.

Interests in shares and performance rights

Direct: 23,885 ordinary shares in nib holdings limited.

Christine McLoughlin

BA, LLB (Hons) (Australian National University), FAICD 
Independent Non-Executive Director

Christine McLoughlin was appointed to the Board of nib holdings limited in March 2011. She is a member of the Risk and Reputation Committee, Audit Committee and Nomination Committee.

Ms McLoughlin is also a Director of nib health funds limited.

Industry Experience

Christine McLoughlin has more than 25 years’ of experience in business with roles as Chair, Director and executive within multiple listed, private and not-for-profit organisations.

Ms McLoughlin is an accomplished company director and business leader, having held senior executive positions in financial services in Australia and internationally. She has also served on the boards of ASX 50 companies in financial services, telecommunications, resources, and infrastructure for the past 12 years. Christine is recognised for achievements in driving continuous improvements in organisational culture and performance, and deep experience in regulatory processes and governance.

Directorships of listed entities

Ms McLoughlin is Chairman of Suncorp Group Limited including Chairman of the Nomination Committee and an ex-officio member of the Audit, Customer, People and Remuneration, and Risk Committees.

Former directorships of listed entities in the last 3 years

Whitehaven Coal Limited and Spark Infrastructure RE Limited.

Other business and market experience

Christine was formerly Chairman, Venues NSW, Deputy Chair of The Smith Family, inaugural Chair of the Australian Payments Council. She was also a Director of each of Westpac’s insurance businesses, as well as the Australian Nuclear Science & Technology Organisation and Victoria’s Transport Accident Commission.

In April 2020, Christine was appointed by the Federal Government as the Private Sector Representative for Australia for the G20 Empowerment and Progression of Women’s Economic Representation (EMPOWER). She has also been involved in several significant Government assignments.

Other commitments

Christine is Chancellor-elect of the University of Wollongong. She is also Chairman and Co-Founder of the Minerva Network and a Director of the McGrath Foundation. She is also a member of the Chief Executive Women, a Fellow of the Australian Institute of Company Directors and a Telstra Business Woman of the Year in 2000.

Interests in shares and performance rights

Indirect: 110,885 shares in nib holdings limited held by Dundas Street Investments Pty Ltd.

Donal O’Dwyer

MBA (Manchester Business School), BE (University College Dublin)
Independent Non-Executive Director

Donal was appointed to the Board of nib holdings limited in March 2016. He is Chair of the Investment Committee, and a member of the Risk and Reputation Committee, People and Remuneration Committee and Nomination Committee.

He is also a Director of nib health funds limited.

Industry Experience

Donal has a deep knowledge of the health industry globally, after more than 35 years in senior executive and Non-Executive Director roles within the healthcare products and medical device sectors.

Starting his career as a qualified civil engineer, he went on to gain experience in business, science, engineering, manufacturing and management. During his tenure with Baxter Healthcare, he rose through the ranks from plant manager to President of the Cardiovascular Group Europe, gaining a sound understanding of the inner workings of business strategy and fiscal management, from the floor of the factory through to the boardroom. He then worked for Cordis (the cardiovascular device franchise of Johnson & Johnson) – initially as European President and later, when he located to the US, he served as Worldwide President.

In his role as member of the nib Risk and Reputation Committee, Donal has a strong interest in environmental, social and governance factors and how these performance indicators can help promote long-term financial success.

Directorships of listed entities

Donal is a Non-Executive Director of Cochlear Ltd, Mesoblast Ltd (Chair of the Nomination and Remuneration Committee) and Fisher & Paykel Healthcare Corporation Ltd.

Former directorships of listed entities in the last 3 years

Chairman of CardieX Limited (formerly AtCor Medical Holdings Limited).

Interests in shares and performance rights

Indirect: 41,485 shares in nib holdings limited held by Dundrum Investments Pty Ltd.